Thermo Fisher Scientific Receives Moderate Buy Rating as Analysts Adjust Targets

Twenty‑four analysts covering Thermo Fisher Scientific issued an average "Moderate Buy" recommendation, with eighteen buys, four holds and two strong buys. The consensus twelve‑month target price is $613.66. Barclays cut its target to $625 and rated the stock overweight, while Wolfe Research began coverage with an "outperform" rating and a $535 target. Royal Bank of Canada set a $490 target with a "sector perform" rating, Stifel Nicolaus lowered its target to $600 and kept a buy rating, and DZ Bank initiated coverage with a $610 target.

Institutional investors shifted positions in the fourth quarter. J. Stern & Co., Norges Bank, Auto Owners Insurance, T. Rowe Price and Wellington Management increased holdings, collectively owning about 89 % of the stock. Conversely, Motley Fool Wealth Management trimmed its stake by 15.2 % to 45,485 shares. Vanguard, Capital World, Geode Capital, and Franklin Resources each raised their positions. In a related insider trade, COO Luca Pettit sold 400 shares, reducing his ownership by 1.57 %.